ClinicalTrials.Veeva

Menu

Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures (PROTECT)

P

Prof Nicolas Theumann

Status

Enrolling

Conditions

Pathological Fracture
Vertebral Compression Fractures
Facet Joint Arthropathy

Treatments

Device: Vertebroplasty

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT06670404
THU-2023-010

Details and patient eligibility

About

The purpose of this study is to collect clinical and radiographic outcomes in patients undergoing vertebroplasty procedures for the treatment of osteoporotic or pathological fractures of the vertebral body to understand the role of sagittal balance in patient outcomes. To support this objective, the sagittal balance measurement of sagittal vertical axis (SVA), NRS back pain, Quebec Back Pain Disability Scale (Quebec) score, and complications will be collected. The secondary purpose of the study is to review the role of sagittal balance and adjacent facet joint arthropathy treatment in patients with vertebral body fractures due to osteoporosis or tumor.

Enrollment

130 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients >18 years.
  • Patients requiring vertebroplasty for the fixation of symptomatic pathological fractures of the thoracic or lumbar vertebral body resulting from osteoporosis or tumor.
  • Symptomatic vertebral compression fracture(s) confirmed by MRI with bone marrow oedema on T2/STIR sequences.
  • Diagnosis of osteoporosis (clinically and confirmed on DXA with quantifiable BMD) or pathological fracture due to tumor
  • Patients with 1 or more vertebral compression fractures of the thoracic or lumbar spine Note: Patients with a current vertebral compression fracture who also have a previous history of vertebral compression fractures of the thoracic or lumbar spine may be included.

Study Specific Inclusion Criterion • Signed informed consent

Exclusion criteria

  • Infection
  • Vertebral body collapse to less than 1/3 (33%) of original height
  • Vertebral plana (>90% vertebral body collapse)
  • Spinal stenosis (retro pulsed fragments).
  • Unstable spine warranting surgical stabilization
  • Prophylactic treatment of any vertebrae with vertebroplasty
  • Irreversible life threating bleeding disorders
  • End stage kidney disease
  • Drug dependence (IVDU)
  • Pregnancy

Study Specific Exclusion Criterion:

• Unable or unwilling to follow the standard of care prescribed follow-up visits

Trial design

130 participants in 1 patient group

Vertebroplasty cohort
Description:
Patients with vertebral compression fractures treated with vertebroplasty
Treatment:
Device: Vertebroplasty

Trial contacts and locations

1

Loading...

Central trial contact

Nicolas Prof Theumann, Medical Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems